Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Amgen Inc. (NASDAQ:AMGN) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. Amgen Inc. (NASDAQ:AMGN) is on ...

Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Strategy” second quarter 2025 ...

(NASDAQ:AMGN) share price is up 22% in the last three years, that falls short of the market return. Disappointingly, the ...

Amgen's expanding rare disease and biosimilar portfolios, coupled with growth potential and dividend history make AMGN stock ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an eight-week period.

Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...

Amgen Inc. closed 14.87% below its 52-week high of $346.85, which the company reached on July 25th.

Amgen can move forward with its takeover of Horizon Therapeutics after the FTC said it had accepted a settlement that the combined company won’t bundle two of Horizon’s blockbuster drugs.

Amgen, based in Thousand Oaks, Calif., said it would pay $52 a share for ChemoCentryx. Photo: Patrick T. Fallon/Bloomberg News. Amgen Inc. agreed to pay $3.7 billion in cash to acquire ...

Amgen said on Wednesday its drug helped to reduce the risk of flares in patients with an immune system-related condition, meeting the main goal of a late-stage study. Skip to main content.

WASHINGTON—The Federal Trade Commission said Friday it had agreed to end its legal challenge of drugmaker Amgen’sAMGN3.32%increase; green up pointing triangle $27.8 billion deal to buy Horizon ...